UROVANT SCIENCES INC

Company Profile:

Urovant Sciences Inc. is a biopharmaceutical company headquartered in the United States. It specializes in the development and commercialization of innovative therapies for urologic conditions. The company focuses on scientific research, clinical development, and bringing new medicines to market to address unmet medical needs in urology. Urovant Sciences Inc. was acquired by Sumitomo Pharma Co., Ltd.

Classification:

Urovant Sciences Inc. is a biopharmaceutical company. It is not a factory and it is not a trader in India. Its primary business involves drug development and commercialization.

Urovant Sciences Inc. primarily focuses on the development and commercialization of therapies for urological conditions. Their main product is:

Vibegron

This medication is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. It is marketed under the brand name Gemtesa in the United States and Kandybar in Canada.

Urovant Sciences Inc. is a US-based biopharmaceutical company. While its parent company, Sumitomo Pharma, has a global presence, Urovant Sciences Inc.'s specific products like Gemtesa are primarily marketed and sold in the United States and Canada. There is no information indicating that Urovant Sciences Inc. manufactures or directly sells these products in India.